Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Aethlon Medical Inc. Stories

2014-04-09 08:30:08

SAN DIEGO, April 9, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b In the coming months, we plan to initiate the first FDA approved study of Hemopurifier® therapy in the United States. Historically, U.S. clinical progression of extracorporeal devices directed toward a single disease indication has been a proven model for value...

2014-03-05 08:29:37

Discoveries Could Have Implications in the Diagnosis, Monitoring and Treatment of Alzheimer's Disease, Chronic Traumatic Encephalopathy and Traumatic Brain Injury SAN DIEGO, March 5, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications...

2014-02-26 08:29:00

SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that that it has reached an agreement in principle with DaVita Clinical Research® (DCR) to provide clinical management services that will support forthcoming studies of the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class therapeutic...

2014-01-07 12:26:52

SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQX:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Biotech Showcase(TM) 2014 conference on Tuesday, January 14(th), at 4:30PM PST. Mr. Joyce's presentation will include an update on a forthcoming FDA-cleared study...

2013-11-07 12:28:05

SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Company Chairman and CEO, Jim Joyce will present a corporate overview at the SeeThruEquity Investor Conference on November 12(th) at 10:30 am Eastern Standard Time (EST). Mr. Joyce's presentation will be webcast via the following link: http://wsw.com/webcast/seethru5/AEMD. The conference will be held at Convene Midtown East (730 Third Avenue), New York City. Additional details can be...

2013-11-04 12:27:42

SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) (Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO) As a follow-up to my October 15(th) note, I am pleased to inform shareholders and other interested parties that we will host a grand opening event for our Exosome Sciences, Inc. (ESI) subsidiary on...

2013-10-24 08:36:23

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) (Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO) Last week, the Wall Street Journal published an informative article on the emergence of cancer immunotherapies designed to augment the immune system's ability to recognize and combat malignant...

2013-10-15 08:31:57

SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO) (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) In recent months, we launched and staffed a diagnostic subsidiary, expanded our intellectual property portfolio, and continued to generate revenues from established and newly awarded government...

2013-09-26 08:28:02

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Defense Advanced Research Projects Agency (DARPA) has exercised an option agreement to proceed with year-three of a five-year $6.8 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics...

2013-09-24 08:30:56

SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Dr. Cicek Gercel-Taylor has been appointed Clinical Research Director of Exosome Sciences, Inc. (ESI), a wholly-owned diagnostic subsidiary of Aethlon Medical. In this role, Dr. Gercel-Taylor will direct and plan the execution of diagnostic clinical programs and interact with collaborative partners and regulatory authorities. (Logo:...